Synthesis, hypnotic properties and molecular modeling studies of 1,2,7,9-tetraaza-spiro[4.5]dec-2-ene-6,8,10-triones

European Journal of Medicinal Chemistry

Volumn 46, Issue 10, 2011, Pages 4964-4969

  Girgis, Adel S ^a   Farag, Hanaa ^a   Ismail, Nasser S M ^b   George, Riham F ^c  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b African Union Organization St Abbassia   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

1,2,7,9 Tetraaza spiro 4.5 dec 2 ene 6,8,10 triones; 5 Arylidene 1,3 dimethyl 2,4,6 pyrimidinetriones; Hydrazonoyl halides; Hypnotics; Molecular modeling

Indexed keywords

1 (3 CHLOROPHENYL) 4 (4 CHLOROPHENYL) 7,9 DIMETHYL 3 PHENYL 1,2,7,9 TETRAAZA SPIRO[4.5]DEC 2 ENE 6,8,10 TRIONE; 1 (3 CHLOROPHENYL) 7,9 DIMETHYL 3,4 DIPHENYL 1,2,7,9 TETRAAZA SPIRO[4.5]DEC 2 ENE 6,8,10 TRIONE; 4 (2,4 DICHLOROPHENYL) 7,9 DIMETHYL 1,3 DIPHENYL 1,2,7,9 TETRAAZA SPIRO[4.5]DEC 2 ENE 6,8,10 TRIONE; 4 (4 CHLOROPHENYL) 7,9 DIMETHYL 1,3 DIPHENYL 1,2,7,9 TETRAAZA SPIRO[4.5]DEC 2 ENE 6,8,10 TRIONE; 4 (4 FLUOROPHENYL) 7,9 DIMETHYL 1,3 DIPHENYL 1,2,7,9 TETRAAZA SPIRO[4.5]DEC 2 ENE 6,8,10 TRIONE; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; 7,9 DIMETHYL 1,3 DIPHENYL 4 (2 THIENYL) 1,2,7,9 TETRAAZA SPIRO[4.5]DEC 2 ENE 6,8,10 TRIONE; 7,9 DIMETHYL 1,3 DIPHENYL 4 (4 METHOXYPHENYL) 1,2,7,9 TETRAAZA SPIRO[4.5]DEC 2 ENE 6,8,10 TRIONE; 7,9 DIMETHYL 1,3 DIPHENYL 4 (4 METHYLPHENYL) 1,2,7,9 TETRAAZA SPIRO[4.5]DEC 2 ENE 6,8,10 TRIONE; 7,9 DIMETHYL 1,3 DIPHENYL 4 (5 METHYL 2 FURANYL) 1,2,7,9 TETRAAZA SPIRO[4.5]DEC 2 ENE 6,8,10 TRIONE; 7,9 DIMETHYL 1,3,4 TRIPHENYL 1,2,7,9 TETRAAZA SPIRO[4.5]DEC 2 ENE 6,8,10 TRIONE; 7,9 DIMETHYL 4 (4 DIMETHYLAMINOPHENYL) 1,3 DIPHENYL 1,2,7,9 TETRAAZA SPIRO[4.5]DEC 2 ENE 6,8,10 TRIONE; HYPNOTIC AGENT; THIOPENTAL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG POTENTIATION; DRUG SYNTHESIS; HYPNOTIC SUSCEPTIBILITY; HYPOTHESIS; IN VIVO STUDY; LETHAL DOSE; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; MORTALITY; MOUSE; NONHUMAN; PHARMACOPHORE; SLEEP TIME; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DISCOVERY; HYPNOTICS AND SEDATIVES; MICE; MODELS, MOLECULAR; PYRIMIDINONES; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPENTAL;

EID: 80053207544     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.07.058     Document Type: Article

References (38)

1. M. Ozawa, K. Honda, I. Nakai, A. Kishida, and A. Ohsaki Bioorg. Med. Chem. Lett. 18 2008 3992 3994
2. A.N. Vgontzas, A. Kales, and E.O. Bixler Pharmacology 51 1995 205 223
3. H.I. El-Subbagh, H.A. El-Kashef, A.A. Kadi, A.A.-M. Abdel-Aziz, G.S. Hassan, J. Tettey, and J. Lehmann Bioorg. Med. Chem. Lett. 18 2008 72 77
4. E.N. Peterson Drugs Future 12 1987 1043 1053
5. W. Sieghart Trends Pharmacol. Sci. 13 1992 446 450
6. E. Sigel, and E.A. Barnard J. Biol. Chem. 259 1984 7219 7223
7. F.A. Stephenson Biochem. J. 310 1995 1 9
8. B. Frølund, B. Ebert, U. Kristiansen, T. Liljefors, and P.K. Larsen Curr. Top. Med. Chem. 2 2002 817 832
9. S.Y. Tsang, and H. Xue Curr. Pharm. Des. 10 2004 1035 1044
10. G.A. Johnston Pharmacol. Ther 69 1996 173 198
11. W.E. Haefely Eur. Arch. Psychiatry Neurol. Sci. 238 1989 294 301
12. R.W. Olsen J. Neurochem. 37 1981 1 13
13. W. Sieghart Pharmacol. Rev. 47 1995 181 234
14. R.K. Goel, V. Kumar, and M.P. Mahajan Bioorg. Med. Chem. Lett. 15 2005 2145 2148
15. E.M. Galati, M.T. Monforte, N. Miceli, and E. Raneri Farmaco 56 2001 459 461
16. A.S. Girgis, Y.A. Ibrahim, I.S. Ahmed Farag, and N. Mishriky J. Chem. Res. (S) 2000 508 509
17. A.S. Girgis, N.S.M. Ismail, H. Farag, W.I. El-Eraky, D.O. Saleh, S.R. Tala, and A.R. Katritzky Eur. J. Med. Chem. 45 2010 4229 4238
18. A.S. Girgis, F.F. Barsoum, and A. Samir Eur. J. Med. Chem. 44 2009 2447 2451
19. N. Mishriky, A.S. Girgis, H.M. Hosni, and H. Farag J. Heterocycl. Chem. 43 2006 1549 1556
20. A.S. Girgis J. Chem. Res. (S) 2006 81 83
21. A.S. Girgis, Y.A. Ibrahim, N. Mishriky, J.N. Lisgarten, B.S. Potter, and R.A. Palmer Tetrahedron 57 2001 2015 2019
22. M.J.S. Dewar, E.G. Zoebisch, E.F. Healy, and J.J.P. Stewart J. Am. Chem. Soc. 107 1985 3902 3909
23. J.J.P. Stewart J. Comput. Chem. 10 1989 209 220
24. J.J.P. Stewart J. Comput. Chem. 10 1989 221 264
25. P. Machado, P.T. Campos, G.R. Lima, F.A. Rosa, A.F.C. Flores, H.G. Bonacorso, N. Zanatta, and M.A.P. Martins J. Mol. Struct. 917 2009 176 182
26. C.P. Frizzo, M.R.B. Marzari, D.N. Moreira, P.T. Campos, N. Zanatta, H.G. Bonacorso, and M.A.P. Martins J. Mol. Struct. 981 2010 71 79
27. H.G. Vogel Drug Discovery and Evaluation, Pharmacological Assays 2nd ed. 2002 Springer 495-496 pp.
28. T. Balazs, and H.C. Grice Toxicol. Appl. Pharmacol 5 1963 387 391
29. A.S. Girgis, N. Mishriky, M. Ellithey, H.M. Hosni, and H. Farag Bioorg. Med. Chem. 15 2007 2403 2413
30. F. Yoneda, and T. Nagamatsu Bull. Chem. Soc. Japan 48 1975 1484 1489
31. K. Tanaka, X. Chen, T. Kimura, and F. Yoneda Chem. Pharm. Bull. 36 1988 60 69
32. Y. Xu Jr., and W.R. Dolbier Tetrahedron 54 1998 6319 6328
33. S. Akabori J. Chem. Soc. Jpn. 52 1931 601 605 Chem. Abstr. 26 (1932) 5077
34. K.A. Krasnov, V.G. Kartsev, and A.S. Gorovoi Chem. Nat. Compd. 36 2000 192 197
35. R. Huisgen, M. Seidel, G. Wallbillich, and H. Knupfer Tetrahedron 17 1962 3 29
36. A.F. Hegarty, J.A. Kearney, and F.L. Scott J. Chem. Soc. Perkin Trans. 2 1973 1422 1430
37. A. Altomare, G. Cascarano, C. Giacovazzo, A. Guagliardi, M.C. Burla, G. Polidori, and M. Camalli J. Appl. Cryst. 27 1994 435 436
38. S. Mackay, C.J. Gilmore, C. Edwards, N. Stewart, and K. Shankland maXus Computer Program for the Solution and Refinement of Crystal Structures 1999 Bruker Nonius/MacScience/The University of Glasgow The Netherlands/Japan